FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Paul La Rosée

Research Profile

Chemicals & Drugs

Disorders

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Physiology

Co-author Network

Publications

TOP 3
Steffen Heublein; Andreas Hochhaus; Britta Höchsmann; Michael Hartmann; Franziska Wehner; Paul La Rosée
Modelling cost effectiveness of horse antithymocyte globulin for treating severe aplastic anaemia in Germany.
Andreas Hochhaus; Paul La Rosée
[Tailored management of chronic myeloid leukemia].
Silvia Bohne; Michael Fritzenwanger; Karim Kentouche; Paul La Rosée; Kai Lehmberg; Iver Petersen; Mathias W Pletz; Orlando Guntinas-Lichius
Fulminant Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Paul La Rosée (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Steffen Heublein; Andreas Hochhaus; Britta Höchsmann; Michael Hartmann; Franziska Wehner; Paul La Rosée
Modelling cost effectiveness of horse antithymocyte globulin for treating severe aplastic anaemia in Germany.
Annals of hematology 2013;92(6):825-30.
2013: Andreas Hochhaus; Paul La Rosée
[Tailored management of chronic myeloid leukemia].
Der Internist 2013;54(2):155-6, 158-60, 162-3.
2013: Silvia Bohne; Michael Fritzenwanger; Karim Kentouche; Paul La Rosée; Kai Lehmberg; Iver Petersen; Mathias W Pletz; Orlando Guntinas-Lichius
Fulminant Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
The Laryngoscope 2013;123(2):362-5.
2012: Mathias Witzens-Harig; M Zaiss; J Atta; C Buske; G Hess; U Keller; P Kiewe; H Kirchner; Paul La Rosée; G Lenz; H Pelz; Christiane Pott; M Reiser; Roland Repp; C Scholz; A Viardot; Martin Dreyling
Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting.
Annals of hematology 2012;91(11):1765-72.
2012: T Klag; Philipp Erben; N Härtel; Andreas Hochhaus; T Schenk; U Schnetzke; J Schwaab; Paul La Rosée
Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors.
Leukemia 2012;26(6):1321-8.
2012: Nicolai Härtel; Andreas Hochhaus; Thomas Klag; Philipp Erben; Benjamin Hanfstein; Martin C Mueller; Thomas Schenk; Paul La Rosée
Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
Journal of cancer research and clinical oncology 2012;138(2):203-12.
2012: Andreas Hochhaus; Thomas Ernst; Andreas Reiter; Paul La Rosée
Imatinib and beyond--targeting activated tyrosine kinases in myeloproliferative disorders.
Onkologie 2012;35 Suppl 1():34-41.
2011: Ulf Schnetzke; Sebastian Scholl; Theo Bossert; Martin Freesmeyer; Andreas Hochhaus; Paul La Rosée
Drug-induced lymphadenopathy with eosinophilia and renal failure mimicking lymphoma disease: dramatic onset of DRESS syndrome associated with antibiotic treatment.
Annals of hematology 2011;90(11):1353-5.
2011: Thomas Ernst; Paul La Rosée; Martin C Müller; Andreas Hochhaus
BCR-ABL mutations in chronic myeloid leukemia.
Hematology/oncology clinics of North America 2011;25(5):997-1008, v-vi.
2010: Paul La Rosée; Michael W N Deininger
Resistance to imatinib: mutations and beyond.
Seminars in hematology 2010;47(4):335-43.
2010: Regina Hermann; Alexander Pfeil; Martin Busch; Christiane Kettner; Daniel Kretzschmar; Andreas Hansch; Paul La Rosée; Gunter Wolf
[Very severe thrombotic thrombocytopenic purpura (TTP) after H1N1 vaccination].
Medizinische Klinik (Munich, Germany : 1983) 2010;105(9):663-8.
2010: Hagop M Kantarjian; Jorge Cortes; Paul La Rosée; Andreas Hochhaus
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Cancer 2010;116(6):1419-30.
2008: Paul La Rosée; Susanne Holm-Eriksen; Heiko Konig; Nicolai Härtel; Thomas Ernst; Julia Debatin; Martin C Mueller; Philipp Erben; Anja Binckebanck; Lydia Wunderle; Yaping Shou; Margaret Dugan; Rüdiger Hehlmann; Oliver G Ottmann; Andreas Hochhaus
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
Haematologica 2008;93(5):765-9.
2008: Paul La Rosée; Andreas Hochhaus
Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications.
Current hematologic malignancy reports 2008;3(2):72-9.
2008: Thomas Ernst; Philipp Erben; Martin C Müller; Peter Paschka; Thomas Schenk; Jana Hoffmann; Sebastian Kreil; Paul La Rosée; Rüdiger Hehlmann; Andreas Hochhaus
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Haematologica 2008;93(2):186-92.
2007: Heiko Konig; Nicolai Härtel; Beate Schultheis; Michael Schatz; Christian Lorentz; Junia V Melo; Rüdiger Hehlmann; Andreas Hochhaus; Paul La Rosée
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
Haematologica 2007;92(6):838-41.
2007: Georgia Metzgeroth; Dietmar Dinter; Philipp Erben; Paul La Rosée; Rüdiger Hehlmann; Jan Hastka
Systemic mastocytosis simulating osseous metastatic disease.
British journal of haematology 2007;136(1):1.
2006: Paul La Rosée; Taiping Jia; Shadmehr Demehri; Nicolai Härtel; Peter de Vries; Lynn Bonham; David Hollenback; Jack W Singer; Junia V Melo; Brian J Druker; Michael W N Deininger
Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6540-6.
2005: Selma Ugurel; Ralf Hildenbrand; Anette Zimpfer; Paul La Rosée; Peter Paschka; Antje Sucker; Petra Keikavoussi; Jürgen C Becker; Werner Rittgen; Andreas Hochhaus; Dirk Schadendorf
Lack of clinical efficacy of imatinib in metastatic melanoma.
British journal of cancer 2005;92(8):1398-405.
2004: Amie S Corbin; Ian J Griswold; Paul La Rosée; Kevin W H Yee; Michael C Heinrich; Corinne L Reimer; Brian J Druker; Michael W N Deininger
Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.
Blood 2004;104(12):3754-7.
2004: Ian J Griswold; Lei J Shen; Paul La Rosée; Shadmehr Demehri; Michael C Heinrich; Rita M Braziel; Laura McGreevey; Andrea Haley; Neill Giese; Brian J Druker; Michael W N Deininger
Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.
Blood 2004;104(9):2912-8.
2004: Martin C Müller; Tanja Hördt; Peter Paschka; Kirsten Merx; Paul La Rosée; Rüdiger Hehlmann; Andreas Hochhaus
Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia.
Acta haematologica 2004;112(1-2):30-3.
2004: Paul La Rosée; Kara Johnson; Amie S Corbin; Eric P Stoffregen; Erika M Moseson; Stephanie Willis; Michael J Mauro; Junia V Melo; Michael W N Deininger; Brian J Druker
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.
Blood 2004;103(1):208-15.
2003: Amie S Corbin; Paul La Rosée; Eric P Stoffregen; Brian J Druker; Michael W N Deininger
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.
Blood 2003;101(11):4611-4.
2003: Paul La Rosée; Lei Shen; Eric P Stoffregen; Michael W N Deininger; Brian J Druker
No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec).
The hematology journal : the official journal of the European Haematology Association / EHA 2003;4(6):413-9.
2002: Paul La Rosée; Amie S Corbin; Eric P Stoffregen; Michael W N Deininger; Brian J Druker
Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).
Cancer research 2002;62(24):7149-53.
2002: Andreas Hochhaus; Sebastian Kreil; Amie S Corbin; Paul La Rosée; Martin C Müller; Tanja Lahaye; B Hanfstein; Claudia Schoch; Nicholas C P Cross; Ute Berger; Harald Gschaidmeier; Brian J Druker; Rüdiger Hehlmann
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Leukemia 2002;16(11):2190-6.
2002: Paul La Rosée; Kara Johnson; Michael O'Dwyer; Brian J Druker
In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
Experimental hematology 2002;30(7):729-37.
2002: Paul La Rosée; Michael O'Dwyer; Brian J Druker
Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.
Leukemia 2002;16(7):1213-9.
2002: Michael O'Dwyer; Paul La Rosée; Ramadevi Nimmanapalli; Kapil N Bhalla; Brian J Druker
Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide.
Seminars in hematology 2002;39(2 Suppl 1):18-21.
2001: Andreas Hochhaus; Sebastian Kreil; Amie S Corbin; Paul La Rosée; Tanja Lahaye; Ute Berger; Nicholas C P Cross; W Linkesch; Brian J Druker; Rüdiger Hehlmann; C Gambacorti- Passerini; G Corneo; M D'Incalci
Roots of clinical resistance to STI-571 cancer therapy.
Science (New York, N.Y.) 2001;293(5538):2163.
2000: Susanne Saussele; Andreas Weisser; Martin C Müller; M Emgi; Paul La Rosée; Peter Paschka; C Kuhn; Andreas Willer; Rüdiger Hehlmann; Andreas Hochhaus
Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes.
Leukemia 2000;14(11):2006-10.
2000: Andreas Hochhaus; Andreas Weisser; Paul La Rosée; Michael Emig; Martin C Müller; Susanne Saussele; Andreas Reiter; C Kuhn; Ute Berger; Rüdiger Hehlmann; Nicholas C P Cross
Detection and quantification of residual disease in chronic myelogenous leukemia.
Leukemia 2000;14(6):998-1005.